0001209191-17-058479.txt : 20171031
0001209191-17-058479.hdr.sgml : 20171031
20171031181502
ACCESSION NUMBER: 0001209191-17-058479
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171031
FILED AS OF DATE: 20171031
DATE AS OF CHANGE: 20171031
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chodakewitz Jeffrey
CENTRAL INDEX KEY: 0001610876
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 171166867
MAIL ADDRESS:
STREET 1: C/O TETRAPHASE PHARMACEUTICALS, INC.
STREET 2: 480 ARSENAL ST., SUITE 101
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-10-31
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001610876
Chodakewitz Jeffrey
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP GMDA, CMO
Common Stock
2017-10-31
4
S
0
1400
142.38
D
113024
D
Common Stock
2017-10-31
4
S
0
4100
143.46
D
108924
D
Common Stock
2017-10-31
4
S
0
25784
144.46
D
83140
D
Common Stock
2017-10-31
4
S
0
19016
145.26
D
64124
D
Common Stock
2017-10-31
4
S
0
4700
146.52
D
59424
D
Common Stock
2017-10-31
4
S
0
3400
147.75
D
56024
D
Common Stock
2017-10-31
4
S
0
1400
148.40
D
54624
D
Common Stock
2017-10-31
4
S
0
200
149.34
D
54424
D
Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $142.38 (range $141.83 to $142.81).
Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $143.46 (range $142.87 to $143.85).
Open market sales reported on this line occurred at a weighted average price of $144.46 (range $143.90 to $144.89).
Open market sales reported on this line occurred at a weighted average price of $145.26 (range $144.91 to $145.87).
Open market sales reported on this line occurred at a weighted average price of $146.52 (range $146.16 to $147.14).
Open market sales reported on this line occurred at a weighted average price of $147.75 (range $147.18 to $148.15).
Open market sales reported on this line occurred at a weighted average price of $148.40 (range $148.19 to $148.70).
/s/ Omar White, Attorney-in-Fact
2017-10-31